TargAnox

TargAnox operated as an early-stage drug discovery company focused on creating novel treatments for conditions arising from oxidative stress. The firm's scientific approach centered on developing therapeutics designed to target the reversible oxidation of cysteine thiols, a key regulatory mechanism for protein function. This strategy aimed to address diseases such as cancer by specifically targeting cysteine residues in their oxidized state.

The company was established in 2009 and secured $5.1 million in a Series A financing round on March 30 of the same year. This investment was led by Ascent Biomedical Ventures and included participation from Partners Innovation Fund. TargAnox's business was rooted in the biotechnology and pharmaceutical sector, concentrating on the initial research and discovery phases of drug development. Its primary clients would have been larger pharmaceutical companies through potential licensing or acquisition deals following successful pre-clinical and clinical milestones. The company is reported to have ceased operations around November 2016.

Keywords: oxidative stress therapeutics, drug discovery, cysteine oxidation, cancer treatment, metabolic diseases, Ascent Biomedical Ventures, Partners Innovation Fund, protein function regulation, targeted therapy, biopharmaceutical R&D, early-stage biotech, cysteine thiols, drug development, protein modification, therapeutic antibodies, preclinical research